The stock of Design Therapeutics Inc (NASDAQ: DSGN) has decreased by -0.31 when compared to last closing price of 3.20.Despite this, the company has seen a loss of -1.24% in its stock price over the last five trading days. investorplace.com reported 2024-05-22 that Biotech stocks are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company.
Is It Worth Investing in Design Therapeutics Inc (NASDAQ: DSGN) Right Now?
The stock has a 36-month beta value of 1.82. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for DSGN is 33.17M, and at present, short sellers hold a 8.64% of that float. On July 04, 2024, the average trading volume of DSGN was 246.92K shares.
DSGN’s Market Performance
The stock of Design Therapeutics Inc (DSGN) has seen a -1.24% decrease in the past week, with a -21.62% drop in the past month, and a -13.78% fall in the past quarter. The volatility ratio for the week is 6.08%, and the volatility levels for the past 30 days are at 5.49% for DSGN. The simple moving average for the past 20 days is -11.87% for DSGN’s stock, with a 8.86% simple moving average for the past 200 days.
Analysts’ Opinion of DSGN
Many brokerage firms have already submitted their reports for DSGN stocks, with Piper Sandler repeating the rating for DSGN by listing it as a “Overweight.” The predicted price for DSGN in the upcoming period, according to Piper Sandler is $12 based on the research report published on May 07, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see DSGN reach a price target of $6, previously predicting the price at $42. The rating they have provided for DSGN stocks is “Neutral” according to the report published on November 14th, 2023.
Wedbush gave a rating of “Neutral” to DSGN, setting the target price at $6 in the report published on August 15th of the previous year.
DSGN Trading at -18.37% from the 50-Day Moving Average
After a stumble in the market that brought DSGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.61% of loss for the given period.
Volatility was left at 5.49%, however, over the last 30 days, the volatility rate increased by 6.08%, as shares sank -21.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.99% lower at present.
During the last 5 trading sessions, DSGN fell by -1.24%, which changed the moving average for the period of 200-days by +24.12% in comparison to the 20-day moving average, which settled at $3.58. In addition, Design Therapeutics Inc saw 20.38% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DSGN starting from Schmid John P., who purchase 17,809 shares at the price of $3.74 back on Mar 25 ’24. After this action, Schmid John P. now owns 26,965 shares of Design Therapeutics Inc, valued at $66,606 using the latest closing price.
Berger Heather A., the Director of Design Therapeutics Inc, purchase 1,300 shares at $3.74 during a trade that took place back on Mar 25 ’24, which means that Berger Heather A. is holding 1,300 shares at $4,866 based on the most recent closing price.
Stock Fundamentals for DSGN
Current profitability levels for the company are sitting at:
- -84.65 for the present operating margin
- 0.33 for the gross margin
The net margin for Design Therapeutics Inc stands at -70.02. The total capital return value is set at -0.26. Equity return is now at value -20.15, with -19.44 for asset returns.
Based on Design Therapeutics Inc (DSGN), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -18.62. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -549.91.
Currently, EBITDA for the company is -78.19 million with net debt to EBITDA at 0.38. When we switch over and look at the enterprise to sales, we see a ratio of 183.41. The receivables turnover for the company is 0.5for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 38.61.
Conclusion
To sum up, Design Therapeutics Inc (DSGN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
